ITGR

Business Context and Reporting Period

Company: Greatbatch, Inc. (Note: Metadata listed "Integer Holdings Corp," but the filing text identifies the registrant as Greatbatch, Inc.)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended April 2, 2010
Business Overview: Greatbatch operates two reportable segments: Greatbatch Medical (components for cardiac rhythm management, neuromodulation, vascular, and orthopaedics) and Electrochem Solutions (electrochemical cells and wireless sensors for industrial and medical applications).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Sales decreased 6% year-over-year to $132.0 million, primarily due to customer inventory stocking in the prior year and an uncertain economic environment affecting the orthopaedics and energy markets. However, sales increased 5% sequentially from Q4 2009.
• Profitability: Net income declined 17% to $5.5 million. While operating margins remained flat at 10.6%, the effective tax rate increased to 35.0% from 31.5% due to the expiration of the U.S. R&D tax credit at the end of 2009.
• Expense Trends:
  • SG&A: Decreased 16% to $15.7 million due to consolidation initiatives and lower performance-based compensation.
  • R&D: Increased 40% to $11.0 million, reflecting strategic investments in new technologies and lower customer cost reimbursements.
  • Restructuring: Other operating expenses dropped 65% to $1.0 million as major facility shutdown and consolidation costs from 2007-2008 wound down.
• Cash Flow Improvement: Operating cash flow surged to $21.2 million from $0.06 million in the prior year, driven by improved working capital management (reduced inventory and receivables) and lower restructuring costs.

Guidance, Outlook, and Risks

• 2010 Sales Outlook: Management expects annual sales growth of 2-5% for CRM/Neuromodulation, 3-7% for Vascular, 3-7% for Orthopaedics, and 0-5% for Electrochem.
• Margin Target: Full-year adjusted operating margin is targeted at 12.0% to 13.5% of sales.
• Capital Allocation: Excess cash flow is expected to be used for capital expenditures ($20-30 million for 2010) and debt reduction. The company plans to repay $30.5 million of convertible notes due in June 2010 using cash on hand.
• Key Risks and Contingencies:
  • Electrochem Litigation: The company is appealing a $34.5 million jury verdict. A bond was posted to stay the judgment, utilizing $35 million of the letter of credit subfacility. The insurer is disputing coverage.
  • Health Care Reform: The Patient Protection and Affordable Care Act could impact revenue and costs, though the full effect is unknown pending regulations.
  • Customer Concentration: Four customers accounted for 63% of total sales in Q1 2010.
  • Raw Materials: Reliance on limited suppliers for critical raw materials (including precious metals) poses inflation risk.

Investor Verification Checklist

• Verify the status and potential financial impact of the Electrochem Litigation appeal and the insurer's declaratory judgment suit.
• Monitor the June 2010 put option on $30.5 million of convertible subordinated notes (CSN I) and the company's liquidity position to ensure repayment capability.
• Assess the impact of Health Care Reform regulations on the orthopaedics and vascular segments, which are sensitive to elective procedure volumes.
• Track customer inventory levels, particularly in the orthopaedics and energy markets, to gauge the sustainability of sequential sales growth.
• Review the credit facility covenants (leverage ratio and interest coverage) to ensure continued compliance, especially given the litigation accruals excluded from covenant calculations.